Published in J Clin Psychiatry on May 04, 2010
Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry (2013) 1.31
Sleep deprivation impairs performance in the 5-choice continuous performance test: similarities between humans and mice. Behav Brain Res (2013) 0.95
Rapid antidepressant effects: moving right along. Mol Psychiatry (2013) 0.93
Serotonergic dysfunction in patients with bipolar disorder assessed by the loudness dependence of the auditory evoked potential. Psychiatry Investig (2012) 0.89
A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy. Front Behav Neurosci (2014) 0.89
Antidepressants and psychostimulants in pediatric populations: is there an association with mania? Paediatr Drugs (2011) 0.84
Sleep and dreaming are for important matters. Front Psychol (2013) 0.83
Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. J Psychiatry Neurosci (2014) 0.81
Euthymia, depression, and mania: what do we know about the switch? Biol Psychiatry (2012) 0.79
Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci (2015) 0.79
Further evidence for ClockΔ19 mice as a model for bipolar disorder mania using cross-species tests of exploration and sensorimotor gating. Behav Brain Res (2013) 0.78
Blue-blocking glasses as additive treatment for mania: a randomized placebo-controlled trial. Bipolar Disord (2016) 0.77
Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania. Int J Neuropsychopharmacol (2014) 0.77
Investigating the mechanism(s) underlying switching between states in bipolar disorder. Eur J Pharmacol (2015) 0.77
Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies. Neurosci Biobehav Rev (2015) 0.77
The noradrenaline metabolite MHPG is a candidate biomarker between the depressive, remission, and manic states in bipolar disorder I: two long-term naturalistic case reports. Neuropsychiatr Dis Treat (2015) 0.76
Anticholinergic mechanisms: a forgotten cause of the switch process in bipolar disorder. J Clin Psychiatry (2010) 0.75
Increased sleep duration precedes the improvement of other symptom domains during the treatment of acute mania: a retrospective chart review. BMC Psychiatry (2016) 0.75
Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder. Medicine (Baltimore) (2016) 0.75
Glial-specific gene alterations associated with manic behaviors. Int J Bipolar Disord (2013) 0.75
Mania Induced by Garcinia cambogia: A Case Series. Prim Care Companion CNS Disord (2016) 0.75
Mood Disorder as an Early Presentation of Epidermoid of Quadrigeminal Cistern. J Neurosci Rural Pract (2017) 0.75
Predictors of a Shorter Time to Hospitalization in Patients with Bipolar Disorder: Medication during the Acute and Maintenance Phases and Other Clinical Factors. Clin Psychopharmacol Neurosci (2017) 0.75
Bipolar mood state reflected in cortico-amygdala resting state connectivity: A cohort and longitudinal study. J Affect Disord (2017) 0.75
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell (2003) 12.50
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry (2004) 4.72
Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A (2007) 3.92
Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry (2002) 3.78
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry (2008) 3.28
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry (2003) 3.14
Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand (2007) 2.89
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry (2001) 2.70
Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry (1995) 2.53
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry (1994) 1.96
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord (1983) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
Historical perspectives and natural history of bipolar disorder. Biol Psychiatry (2000) 1.61
Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J Neurosci (2000) 1.60
Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry (2006) 1.58
Recurrent cases of corticosteroid-induced mood disorder: clinical characteristics and treatment. J Clin Psychiatry (2000) 1.55
Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry (1987) 1.55
Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol (2006) 1.54
Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc Natl Acad Sci U S A (2004) 1.54
Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry (2001) 1.53
Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry (2005) 1.52
Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet B Neuropsychiatr Genet (2003) 1.50
Corticosteroid-induced mania after single regional application at the celiac plexus. Anesthesiology (1996) 1.50
Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry (2008) 1.36
Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry (2006) 1.36
Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev (2007) 1.36
Prednisone effects on neurochemistry and behavior. Preliminary findings. Arch Gen Psychiatry (1990) 1.35
Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology (2005) 1.34
Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry (1979) 1.33
Protein kinase Cbeta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice. J Pharmacol Exp Ther (2008) 1.31
Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Res (1999) 1.29
Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry (2007) 1.26
Sleep deprivation in the rat: an animal model of mania. Eur Neuropsychopharmacol (1995) 1.25
Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disord (2003) 1.24
Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am (2005) 1.21
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand (2008) 1.19
Relationship between sleep and mood in patients with rapid-cycling bipolar disorder. Psychiatry Res (1996) 1.19
Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl) (1994) 1.17
Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther (1972) 1.16
Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry (2008) 1.14
Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol (1989) 1.14
Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. Psychoneuroendocrinology (1996) 1.13
Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry (2006) 1.12
A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett (2004) 1.11
The use of antidepressants in bipolar disorder. J Clin Psychiatry (2008) 1.11
A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry (2002) 1.10
Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Rev Bras Psiquiatr (2006) 1.10
Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol (2002) 1.09
A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol (1989) 1.05
Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry (2007) 1.04
Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2004) 1.04
Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry (2001) 1.04
Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry (2001) 1.04
Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J (2003) 1.02
A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry (1994) 1.01
The behavioral effects of REM sleep deprivation in rats. Psychophysiology (1970) 1.01
Modulation of brain gene expression during sleep and wakefulness: a review of recent findings. Neuropsychopharmacology (2001) 1.00
Psychosis in a child inhaling budesonide. Lancet (1983) 1.00
The "switch process" in manic-depressive illness. II. Relationship to catecholamines, REM sleep, and drugs. Arch Gen Psychiatry (1972) 1.00
Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry (1991) 0.99
Association of polymorphism (Val66Met) of brain-derived neurotrophic factor with suicide attempts in depressed patients. Neuropsychobiology (2008) 0.99
The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry (2001) 0.98
Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry (2004) 0.98
Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med (1986) 0.97
Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol (2008) 0.97
Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. Psychiatr Genet (2008) 0.97
Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. Am J Psychiatry (1989) 0.97
Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord (2002) 0.97
Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. Br J Psychiatry (2006) 0.96
The induction of mania. A natural history study with controls. Arch Gen Psychiatry (1982) 0.96
Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord (2008) 0.95
Controlled trials in bipolar I depression: focus on switch rates and efficacy. Eur Neuropsychopharmacol (1999) 0.94
Beclomethasone mania. Br J Psychiatry (1989) 0.94
Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord (2006) 0.94
The role of the cingulate gyrus in depression: from functional anatomy to neurochemistry. Biol Psychiatry (1996) 0.94
Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand (2001) 0.94
Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand (2002) 0.94
Rapid switching of mood in families with multiple cases of bipolar disorder. Arch Gen Psychiatry (2003) 0.94
Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biol Psychiatry (1999) 0.93
Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett (2006) 0.93
The unipolar-bipolar dichotomy and the response to sleep deprivation. Psychiatry Res (1998) 0.93
Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM). J Affect Disord (2009) 0.93
A function for REM sleep: regulation of noradrenergic receptor sensitivity. Brain Res (1988) 0.92
Regular induction of hypomania by L-dopa in "bipolar" manic-depressive patients. Nature (1971) 0.90
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord (2001) 0.90
Falret's discovery: the origin of the concept of bipolar affective illness. Translated by M. J. Sedler and Eric C. Dessain. Am J Psychiatry (1983) 0.90
Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology (1988) 0.89
Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics (2008) 0.88
Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm (Vienna) (2002) 0.88
Association of rapid mood switching with panic disorder and familial panic risk in familial bipolar disorder. Am J Psychiatry (2003) 0.88
Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol (2003) 0.87
No association of two common SNPs at position -1727 A/T, -50 C/T of GSK-3 beta polymorphisms with schizophrenia and bipolar disorder of Korean population. Neurosci Lett (2005) 0.87
Biological and behavioral effects of one night's sleep deprivation in depressed patients and normals. J Psychiatr Res (1979) 0.87
Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers. Hum Psychopharmacol (2003) 0.86
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry (2003) 3.00
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry (2002) 1.84
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage (2005) 1.57
Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry (2014) 1.54
The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 1.53
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep (2007) 1.50
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry (2005) 1.48
Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci (2004) 1.45
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology (2007) 1.42
Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007) 1.41
Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology (2008) 1.41
In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology (2004) 1.41
Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med (2010) 1.41
Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry (2007) 1.40
Molecular effects of lithium. Mol Interv (2004) 1.39
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry (2009) 1.33
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol (2012) 1.32
Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry (2013) 1.31
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry (2004) 1.29
The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry (2009) 1.29
Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2008) 1.29
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Differing amygdala responses to facial expressions in children and adults with bipolar disorder. Am J Psychiatry (2012) 1.27
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry (2003) 1.25
BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci U S A (2008) 1.25
Endophenotypes in bipolar disorder. Am J Med Genet (2002) 1.25
Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24
Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology (2006) 1.24
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology (2010) 1.24
Bipolar disorder: from genes to behavior pathways. J Clin Invest (2009) 1.24
Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics (2010) 1.23
Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry (2006) 1.23
Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets (2006) 1.23
Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response. Neuroreport (2009) 1.23
A developmental study of the neural circuitry mediating motor inhibition in bipolar disorder. Am J Psychiatry (2012) 1.21
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21